drugset
drugset / Trial / NCT03316326

S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer

NCT03316326 ↗

Phase 2 Unknown 35 enrolled National Taiwan University Hospital TTY Biopharm · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase II clinical trial will enroll patients with newly-diagnosed locally-advanced pancreatic adenocarcinoma and adopt the Simon's two-stage optimum design. After 4 cycles of SIROX regimen, patients will proceed to curative resection.

Timeline

Start
2017-11-01
Primary completion
2021-12-31
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule 150 mg/m2 —
Subject Oxaliplatin Small molecule 85 mg/m2 —
Subject tegafur-gimeracil-oteracil potassium Small molecule 40 mg —

Indications

pancreatic ductal adenocarcinoma